These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 21351188)

  • 1. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.
    Schilder CM; Seynaeve C; Linn SC; Boogerd W; Beex LV; Gundy CM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
    Psychooncology; 2012 May; 21(5):479-87. PubMed ID: 21351188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
    Schilder CM; Eggens PC; Seynaeve C; Linn SC; Boogerd W; Gundy CM; Beex LV; Van Dam FS; Schagen SB
    Acta Oncol; 2009; 48(1):76-85. PubMed ID: 18777410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
    Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
    J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
    Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
    Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer.
    Boele FW; Schilder CM; de Roode ML; Deijen JB; Schagen SB
    Menopause; 2015 Jan; 22(1):17-25. PubMed ID: 24977455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.
    Castellon SA; Ganz PA; Bower JE; Petersen L; Abraham L; Greendale GA
    J Clin Exp Neuropsychol; 2004 Oct; 26(7):955-69. PubMed ID: 15742545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
    van Nes JG; Beex LV; Seynaeve C; Putter H; Sramek A; Lardenoije S; Duijm-de Carpentier M; Van Rongen I; Nortier JW; Zonderland HM; van de Velde CJ
    Acta Oncol; 2015 Mar; 54(3):349-60. PubMed ID: 25383451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.
    Breckenridge LM; Bruns GL; Todd BL; Feuerstein M
    Psychooncology; 2012 Jan; 21(1):43-53. PubMed ID: 20967847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
    Jones SE; Cantrell J; Vukelja S; Pippen J; O'Shaughnessy J; Blum JL; Brooks R; Hartung NL; Negron AG; Richards DA; Rivera R; Holmes FA; Chittoor S; Whittaker TL; Bordelon JH; Ketchel SJ; Davis JC; Ilegbodu D; Kochis J; Asmar L
    J Clin Oncol; 2007 Oct; 25(30):4765-71. PubMed ID: 17947724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.
    Schilder CM; Seynaeve C; Linn SC; Boogerd W; Beex LV; Gundy CM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
    Crit Rev Oncol Hematol; 2010 Nov; 76(2):133-41. PubMed ID: 20036141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatigue, anxiety and depression overrule the role of oncological treatment in predicting self-reported health complaints in women with breast cancer compared to healthy controls.
    Hagen KB; Aas T; Kvaløy JT; Eriksen HR; Søiland H; Lind R
    Breast; 2016 Aug; 28():100-6. PubMed ID: 27262826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study.
    van Nes JG; Fontein DB; Hille ET; Voskuil DW; van Leeuwen FE; de Haes JC; Putter H; Seynaeve C; Nortier JW; van de Velde CJ
    Breast Cancer Res Treat; 2012 Jul; 134(1):267-76. PubMed ID: 22453754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
    Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
    Psychooncology; 2009 Aug; 18(8):811-21. PubMed ID: 19085975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.
    Fan HG; Houédé-Tchen N; Yi QL; Chemerynsky I; Downie FP; Sabate K; Tannock IF
    J Clin Oncol; 2005 Nov; 23(31):8025-32. PubMed ID: 16258100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
    N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing a novel account of the dissociation between self-reported memory problems and memory performance in chemotherapy-treated breast cancer survivors.
    Paquet L; Verma S; Collins B; Chinneck A; Bedard M; Song X
    Psychooncology; 2018 Jan; 27(1):171-177. PubMed ID: 28129471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer.
    Merriman JD; Sereika SM; Brufsky AM; McAuliffe PF; McGuire KP; Myers JS; Phillips ML; Ryan CM; Gentry AL; Jones LD; Bender CM
    Psychooncology; 2017 Jan; 26(1):44-52. PubMed ID: 26486371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy and cognitive complaints in women with breast cancer.
    Pullens MJ; De Vries J; Van Warmerdam LJ; Van De Wal MA; Roukema JA
    Psychooncology; 2013 Aug; 22(8):1783-9. PubMed ID: 23109296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.